PriceTargets.com logo

NASDAQ:PRTA - Prothena Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $63.89
  • Forecasted Upside: -15.18 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$75.32 As of 09/24/2021 01:00 AM ET
▼ -3.57 (-4.53%)

This chart shows the closing price for PRTA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Prothena Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRTA

Analyst Price Target is $63.89
▼ -15.18% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for Prothena in the last 3 months. The average price target is $63.89, with a high forecast of $103.00 and a low forecast of $14.00. The average price target represents a -15.18% upside from the last price of $75.32.

This chart shows the closing price for PRTA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 investment analysts is to buy stock in Prothena. This rating has held steady since December 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/4/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/28/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/27/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/27/2021OppenheimerBoost Price TargetOutperform$90.00 ➝ $100.00Medium
9/20/2021Fox-Davies CapitalInitiated CoverageOverweight$14.00Low
9/17/2021Cantor FitzgeraldBoost Price TargetOverweight$70.00 ➝ $103.00High
9/14/2021OppenheimerBoost Price TargetOutperform$82.00 ➝ $90.00High
8/9/2021OppenheimerBoost Price TargetOutperform$76.00 ➝ $82.00High
7/19/2021Royal Bank of CanadaBoost Price TargetOutperform$50.00 ➝ $59.00Medium
7/15/2021Cantor FitzgeraldBoost Price TargetOverweight$63.00 ➝ $70.00Medium
7/13/2021OppenheimerBoost Price TargetSell ➝ Outperform$54.00 ➝ $76.00High
7/13/2021HC WainwrightBoost Price TargetBuy$58.00 ➝ $75.00Medium
7/13/2021CitigroupBoost Price TargetBuy$57.00 ➝ $72.00Medium
6/25/2021BTIG ResearchBoost Price TargetBuy$29.00 ➝ $65.00High
6/18/2021Bank of AmericaUpgradeUnderperform ➝ Neutral$12.00 ➝ $49.00High
6/11/2021Royal Bank of CanadaBoost Price TargetOutperform$28.00 ➝ $50.00Medium
6/10/2021HC WainwrightBoost Price TargetBuy$33.00 ➝ $58.00High
6/8/2021OppenheimerBoost Price TargetPositive ➝ Outperform$45.00 ➝ $54.00High
6/8/2021Cantor FitzgeraldBoost Price TargetOverweight$43.00 ➝ $62.00High
6/1/2021OppenheimerBoost Price TargetOutperform$40.00 ➝ $45.00High
5/26/2021CitigroupInitiated CoverageBuyHigh
5/12/2021OppenheimerBoost Price TargetOutperform$35.00 ➝ $40.00High
3/15/2021Jefferies Financial GroupBoost Price TargetBuy$30.00 ➝ $38.00High
3/2/2021OppenheimerReiterated RatingBuy$35.00Medium
2/26/2021Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$14.00 ➝ $28.00Medium
2/12/2021Jefferies Financial GroupUpgradeHold ➝ Buy$15.00 ➝ $30.00Low
2/4/2021HC WainwrightBoost Price TargetBuy$22.00 ➝ $33.00Low
2/2/2021OppenheimerBoost Price TargetOutperform$25.00 ➝ $35.00Low
2/2/2021BTIG ResearchUpgradeNeutral ➝ Buy$29.00Low
12/10/2020OppenheimerBoost Price Target$20.00 ➝ $25.00Low
12/7/2020HC WainwrightInitiated CoverageBuy$22.00Low
10/21/2020Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$20.00 ➝ $24.00High
9/13/2020OppenheimerReiterated RatingBuy$18.00High
7/8/2020OppenheimerUpgradeMarket Perform ➝ Outperform$16.00High
5/13/2020OppenheimerReiterated RatingHoldHigh
5/10/2020NomuraReiterated RatingBuy$19.00High
4/23/2020OppenheimerReiterated RatingHoldLow
1/1/2020Nomura SecuritiesReiterated RatingBuy$19.00Low
12/22/2019Evercore ISIReiterated RatingBuy$14.00High
11/27/2019Evercore ISIUpgradeIn-Line ➝ OutperformLow
11/19/2019Evercore ISIUpgradeIn-Line ➝ Outperform$14.00High
5/31/2019BarclaysReiterated RatingSell$9.00Low
5/16/2019Cantor FitzgeraldReiterated RatingOverweightHigh
3/4/2019Cantor FitzgeraldInitiated CoverageOverweight$13.77High
11/23/2018Cantor FitzgeraldReiterated RatingOverweightHigh
11/11/2018OppenheimerReiterated RatingHoldHigh
8/8/2018Cantor FitzgeraldReiterated RatingBuy$18.00Low
6/15/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Buy$14.00 ➝ $18.00High
5/25/2018OppenheimerReiterated RatingHoldLow
5/21/2018BarclaysDowngradeEqual Weight ➝ Underweight$12.00High
5/9/2018OppenheimerReiterated RatingHoldHigh
4/24/2018Nomura SecuritiesLower Price TargetBuy ➝ Buy$87.00 ➝ $19.00High
4/24/2018WedbushLower Price TargetNeutral$46.00 ➝ $13.00High
4/24/2018BTIG ResearchDowngradeBuy ➝ Neutral$77.00High
4/24/2018Deutsche Bank AktiengesellschaftReiterated RatingBuy ➝ Buy$78.00 ➝ $16.00High
4/24/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$69.00 ➝ $14.00High
4/23/2018OppenheimerDowngradeOutperform ➝ HoldHigh
4/23/2018Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$87.00High
4/23/2018BarclaysDowngradeOverweight ➝ Equal WeightHigh
4/23/2018Jefferies Financial GroupDowngradeBuy ➝ HoldHigh
4/5/2018BarclaysLower Price TargetOverweight ➝ Overweight$70.00 ➝ $50.00Medium
3/21/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyHigh
3/21/2018Cantor FitzgeraldReiterated RatingOverweight$69.00High
3/21/2018OppenheimerSet Price TargetBuy$70.00High
2/15/2018OppenheimerSet Price TargetBuy$70.00High
2/4/2018Cantor FitzgeraldReiterated RatingBuy$65.00High
12/20/2017Cantor FitzgeraldReiterated RatingBuy$65.00Medium
12/4/2017OppenheimerSet Price TargetBuy$70.00High
11/20/2017WedbushDowngradeOutperform ➝ Neutral$75.00 ➝ $55.00N/A
11/9/2017OppenheimerReiterated RatingBuy$70.00N/A
10/23/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$73.00N/A
10/2/2017Jefferies Financial GroupReiterated RatingBuy$100.00Low
10/2/2017SunTrust BanksReiterated RatingBuy$75.00Low
10/1/2017Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
9/29/2017Royal Bank of CanadaReiterated RatingBuyHigh
9/29/2017BTIG ResearchLower Price TargetBuy ➝ Buy$80.00 ➝ $77.00High
9/28/2017Cantor FitzgeraldReiterated RatingBuy$79.00Medium
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$87.00High
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$83.00High
7/10/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$100.00Medium
7/6/2017OppenheimerReiterated RatingOutperform$70.00Low
5/19/2017BTIG ResearchInitiated CoverageBuy$80.00High
5/16/2017Piper Jaffray CompaniesReiterated RatingBuyMedium
5/11/2017OppenheimerSet Price TargetBuy$70.00Low
4/12/2017Cantor FitzgeraldInitiated CoverageOverweight$86.00High
4/12/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$69.00Medium
4/6/2017OppenheimerSet Price TargetBuy$70.00Low
4/3/2017WedbushReiterated RatingOutperform$77.00High
3/22/2017OppenheimerReiterated RatingBuyLow
3/1/2017Nomura InstinetInitiated CoverageBuy ➝ Buy$87.00N/A
3/1/2017Nomura SecuritiesInitiated CoverageBuyN/A
2/15/2017WedbushReiterated RatingOutperform$77.00N/A
12/20/2016SunTrust BanksInitiated CoverageBuy$75.00N/A
12/6/2016WedbushReiterated RatingOutperform$77.00N/A
11/10/2016WedbushReiterated RatingOutperform$77.00N/A
11/3/2016Deutsche Bank AktiengesellschaftInitiated CoverageBuy$73.00N/A
10/31/2016WedbushReiterated RatingOutperform$77.00N/A
9/27/2016Credit Suisse GroupReiterated RatingBuy$65.00N/A
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/1/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/31/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/30/2021
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2021
  • 11 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2021
  • 2 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2021
  • 8 very positive mentions
  • 20 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2021

Current Sentiment

  • 8 very positive mentions
  • 20 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Prothena logo
Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm's clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $75.32
Low: $74.43
High: $78.61

50 Day Range

MA: $63.21
Low: $48.20
High: $78.89

52 Week Range

Now: $75.32
Low: $9.67
High: $78.95

Volume

7,112 shs

Average Volume

442,549 shs

Market Capitalization

$3.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.5

Frequently Asked Questions

What sell-side analysts currently cover shares of Prothena?

The following sell-side analysts have issued stock ratings on Prothena in the last twelve months: Bank of America Co., BTIG Research, Cantor Fitzgerald, Citigroup Inc., Fox-Davies Capital, HC Wainwright, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., Royal Bank of Canada, and Zacks Investment Research.
View the latest analyst ratings for PRTA.

What is the current price target for Prothena?

9 Wall Street analysts have set twelve-month price targets for Prothena in the last year. Their average twelve-month price target is $62.78, suggesting a possible downside of 16.7%. Cantor Fitzgerald has the highest price target set, predicting PRTA will reach $103.00 in the next twelve months. Fox-Davies Capital has the lowest price target set, forecasting a price of $14.00 for Prothena in the next year.
View the latest price targets for PRTA.

What is the current consensus analyst rating for Prothena?

Prothena currently has 1 hold rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRTA will outperform the market and that investors should add to their positions of Prothena.
View the latest ratings for PRTA.

How do I contact Prothena's investor relations team?

Prothena's physical mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The biotechnology company's listed phone number is (531) 236-2500 and its investor relations email address is [email protected] The official website for Prothena is www.prothena.com.